Eliminate Ghost Peaks in UHPLC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Eliminate Ghost Peaks in UHPLC

Shimadzu has introduced the Ghost Trap™ DS-HP Series Columns which are designed to remove impurities from the solvent and system, enabling highly sensitive and reliable analysis.

These special columns focus on the specific characteristic of the impurities, and their usage can improve the quality of the analytical results dramatically. The Ghost Trap™ DS-HP columns utilise a new packing material with novel carbon technology, available for aqueous as well as for organic solvents. They can eliminate interference peaks not only from the mobile phase and environment but also from HPLC line by locating the column downstream of GE mixer.

Impurities in the HPLC/UHPLC environment often interfere with the real analytes and badly influence the system performance through their appearance as ghost peaks in the chromatogram. Accumulated impurities may elute from the column during gradient elution. Elimination of these contaminations by dedicated columns avoids time-consuming investigations into the background and nature of the contaminants.

Suitable for UHPLC analysis Ghost Trap DS-HP columns offer back pressure tolerance of 100 MPa, well suited to most UHPLC applications in use. They ensure the best performance for high end analysis.

For more information please visit www.shimadzu.eu

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
FindPharma Custom Search

Click here